Stereotaxis flags Robocath deal risks, including dilution and higher operating losses
Stereotaxis completed its acquisition of Robocath, a French medical device company, on July 7, 2026, and filed supplemental risk factors. The filing says the deal will not be accretive and will increase Stereotaxis's operating losses in the near term, and that issuing shares for the earnout could dilute existing stockholders.
Key points
- Stereotaxis issued 6,269,628 closing shares at the July 7, 2026 closing, including 225,000 shares paid to Robocath's financial advisor.
- The Share Sale Agreement allows up to $25 million of earnout consideration, payable in cash, shares, or both, if regulatory and commercial milestones are met.
- Stereotaxis registered 13,179,975 possible earnout shares, with a cap of 19.9% of shares outstanding as of July 7, 2026, including the closing shares.
- Stereotaxis extended $1.1 million in operating loans to Robocath before closing; the loans were repaid at closing and reduced the upfront stock consideration.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.